BusinessWeek's Gene Marcial sized up BioSante Pharmaceutical's pipeline and concluded that its late stage therapy for sexual dysfunction in menopausal women could make it a prime candidate for a buyout. LibiGel began a second Phase III trial recently while data from the first late-stage efficacy study is due out in 2009.
In Marcial's view, BioSante is lining up for a piece of a multibillion-dollar market. And then BioSante did bring in Deutsche bank to assess its strategic alternatives--usually a dead giveaway that a good offer would receive welcoming smiles.
- read the column from BusinessWeek